MedPath

FDA Approves IND Application for NextCure's B7-H4-Targeting ADC, LNCB74, for Solid Tumors

  • The FDA has accepted NextCure's IND application for LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4, paving the way for Phase 1 clinical trials.
  • LNCB74, co-developed with LigaChem Biosciences, aims to treat multiple cancers, including breast, ovarian, and endometrial cancers, by targeting B7-H4 overexpressed in cancer cells.
  • Preclinical data demonstrated LNCB74's potential with complete tumor eradication at low doses and superior anti-tumor efficacy compared to other B7-H4-targeting ADCs.
  • Phase 1 trials, led by NextCure, will begin early next year, including dose escalation and expansion studies to determine safe dosing and confirm therapeutic dosage.
The U.S. Food and Drug Administration (FDA) has accepted NextCure's Investigational New Drug (IND) application for LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4, marking a significant step toward clinical development for multiple cancers. This decision allows NextCure to initiate Phase 1 clinical trials to evaluate LNCB74 as a therapeutic for treating various solid tumors.

LNCB74: A Novel Approach to Targeting B7-H4

LNCB74 is being co-developed by NextCure and LigaChem Biosciences. It combines an antibody that targets the B7-H4 protein, which is commonly overexpressed in cancer cells, with LigaChem Bio’s proprietary ADC platform. The therapy is designed to address cancers such as breast, ovarian, and endometrial cancers, where B7-H4 expression is prevalent.
Michael Richman, NextCure's president and CEO, stated, "Acceptance of the IND application for LNCB74 represents an important milestone for NextCure as we focus our resources on advancing our ADC program. We believe LNCB74 has the potential to transform treatment for patients and we look forward to advancing LNCB74 into clinical development."

Clinical Trial Plans

Following the IND approval, NextCure and LigaChem Biosciences plan to initiate Phase 1 clinical trials early next year. The trials will consist of a dose-escalation study (Phase 1a) to determine safe dosing levels, followed by a dose-expansion study (Phase 1b) to evaluate the therapeutic dosage and confirm indications. NextCure will lead the clinical trials in collaboration with LigaChem Bio’s U.S. subsidiary, ACB, and its clinical experts.

Promising Preclinical Results

Preclinical studies have demonstrated LNCB74’s potential, showing complete tumor eradication even at low doses. Animal studies using patient-derived cancer cells highlighted superior anti-tumor efficacy and safety compared to other ADCs targeting B7-H4.
LigaChem Bio stated, "The outstanding preclinical results affirm LNCB74’s potential as a best-in-class drug. With this IND approval, we anticipate initiating first-in-human dosing early next year, marking a significant step toward global development."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Lin BioScience's investigational drug LBS-007 has been granted Fast Track Designation by the U.S. FDA for treating acute myeloid leukemia, highlighting its potential to address unmet medical needs in acute leukemia treatment. The company is conducting a Phase 1/2 trial in patients with relapsed or resistant acute leukemias across the US, Australia, and Taiwan.

Leads Biolabs' LBL-024 Receives FDA Orphan Drug Designation for Neuroendocrine Cancer

LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB developed by Leads Biolabs, has been granted Orphan Drug Designation by the FDA for neuroendocrine cancer.

LBL-024 Receives FDA Orphan Drug Designation for Neuroendocrine Cancer

LBL-024, an anti-PD-L1/4-1BB bispecific antibody developed by Leads Biolabs, has been granted Orphan Drug Designation by the FDA for neuroendocrine cancer treatment.

AstraZeneca and Daiichi Sankyo Seek FDA Approval for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd).

SystImmune's BL-M17D1 Antibody-Drug Conjugate Receives FDA IND Clearance for Advanced Solid Tumors

SystImmune's BL-M17D1, an antibody-drug conjugate (ADC) with a novel linker and payload, has received FDA IND clearance.

SystImmune's BL-M17D1 Antibody-Drug Conjugate Receives FDA IND Clearance for Advanced Solid Tumors

SystImmune's BL-M17D1, an antibody-drug conjugate (ADC) with innovative linker and payload technology, has received FDA IND clearance for a Phase 1 clinical trial.

ABD-147 and PT217 Receive FDA Orphan Drug Designations for Neuroendocrine Carcinoma Treatment

The FDA granted Orphan Drug Designation to ABD-147, a radiopharmaceutical from Abdera Therapeutics, for neuroendocrine carcinoma, offering potential tax credits and market exclusivity.

FDA's July Roundup: Approvals, Fast Tracks, and Designations in Oncology

The FDA approved FoundationOne Liquid CDx as a companion diagnostic for niraparib and abiraterone in BRCA-mutated metastatic castration-resistant prostate cancer.

FDA Grants Orphan Drug Designation to Mabwell's 7MW3711 for Small Cell Lung Cancer

The FDA has granted Orphan Drug Designation to 7MW3711, a novel B7-H3-targeting antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC).

Reference News

[1]
Press Release > Investors > LigaChem Biosciences
ligachembio.com · Dec 10, 2024

NextCure announced FDA acceptance of an IND application for LNCB74, a B7-H4-targeting ADC for multiple cancers, marking ...

[2]
FDA Approves Liga-Chem Bio's IND for Novel ADC Cancer Therapy - 코메디닷컴
kormedi.com · Dec 11, 2024

FDA approves Liga-Chem Bio’s IND for LNCB74, an ADC targeting B7H4 protein for solid tumors. Preclinical data shows pote...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy